Mizuho raised the firm’s price target on Vaxcyte to $113 from $69 and keeps a Buy rating on the shares post the Q4 report. The analyst says the Vaxcyte story continues to largely hinge on the VAX-31 adult Phase 1/2 study readout in Q3.This is a potentially re-rating event, as positive data here would further increase confidence in the space that Vaxcyte has the broadest serotype vaccine and “best overall mouse-trap” in the $8B and growing pneumococcal disease vaccine market, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PCVX:
- Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
- Vaxcyte completes enrollment of Phase 2 study evaluating VAX-24
- Vaxcyte price target raised to $95 from $73 at Needham
- Vaxcyte price target raised to $98 from $76 at BTIG
- Vaxcyte reports Q 4 net loss $180.8M vs $78.1M last year